The phase I/II CheckMate 358 study investigated nivolumab alone or in combination with ipilimumab as a chemotherapy-free regimen for the first-line treatment, showing manageable toxicity and durable tumor regression regardless of tumor PD-L1 expression in patients with R/M CC. This evidence concerns the gene CD274 and neoplasm.